EMA Authorised: Zyllt (clopidogrel (as hydrogen sulfate)) — Krka, d.d., Novo mesto

View source ↗

Summary

EMA authorised Zyllt, a clopidogrel hydrogen sulfate product by Krka, d.d., Novo mesto. It is indicated for preventing vascular events in patients with peripher…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Peripheral Vascular Disease
• Stroke

Drugs mentioned

• Zyllt (clopidogrel hydrogen sulfate)

Snippet

Status: Authorised. Therapeutic area: Peripheral Vascular Diseases;Stroke;Acute Coronary Syndrome;Myocardial Infarction. MAH: Krka, d.d., Novo mesto. Decision date: 13/05/2025